Next Article in Journal
Pharmacological Studies of Tentacle Extract from the Jellyfish Cyanea capillata in Isolated Rat Aorta
Next Article in Special Issue
Limited Impact of 2 g/day Omega-3 Fatty Acid Ethyl Esters (Omacor®) on Plasma Lipids and Inflammatory Markers in Patients Awaiting Carotid Endarterectomy
Previous Article in Journal
Calcarides A–E, Antibacterial Macrocyclic and Linear Polyesters from a Calcarisporium Strain
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2013, 11(9), 3324-3334; doi:10.3390/md11093324

The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

1
Department of Cardiology, Center for Cardiovascular Research, Aalborg University Hospital, Aalborg 9000, Denmark
2
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg 9000, Denmark
*
Author to whom correspondence should be addressed.
Received: 13 June 2013 / Revised: 1 August 2013 / Accepted: 8 August 2013 / Published: 30 August 2013
(This article belongs to the Special Issue Marine Fatty Acids-2013)
View Full-Text   |   Download PDF [508 KB, uploaded 24 February 2015]   |  

Abstract

CD36 is a scavenger receptor involved in lipid uptake and inflammation. Recently, non-cell-bound CD36 (sCD36) was identified in plasma and suggested to be a marker of lipid accumulation in the vessel wall. Marine n-3 polyunsaturated fatty acids (PUFA) may have cardioprotective effects. This study evaluated the effect of marine n-3 PUFA on sCD36 levels in overweight subjects. Fifty overweight subjects were randomized to 1.1 g of n-3 PUFA or 2 g of olive oil daily for six weeks. Neutrophils were isolated at baseline and after six weeks of treatment while an adipose tissue biopsy was obtained at baseline. The content of n-3 PUFA in adipose tissue and neutrophils was analyzed by gas chromatography, while plasma levels of sCD36 were determined using an enzyme-linked immunosorbent assay (ELISA). After six weeks of supplement plasma sCD36 did not differ between supplements (P = 0.18). There was no significant correlation between plasma sCD36 levels and n-3 PUFA in neutrophils at baseline (r = −0.02, P = 0.88), after six weeks supplement (r = −0.03, P = 0.85) or in adipose tissue (r = 0.14, P = 0.34). This study therefore does not provide evidence for a cardioprotective effect of n-3 PUFA acting through a CD36-dependent mechanism. View Full-Text
Keywords: n-3 PUFA; CD36; adipose tissue; cardiovascular disease; randomised controlled trial n-3 PUFA; CD36; adipose tissue; cardiovascular disease; randomised controlled trial
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Venø, S.K.; Nielsen, M.R.S.; Lundbye-Christensen, S.; Schmidt, E.B.; Handberg, A. The Effect of Low-Dose Marine n-3 Fatty Acids on Plasma Levels of sCD36 in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Mar. Drugs 2013, 11, 3324-3334.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top